BillionToOne, Inc. (BLLN) is a Menlo Park–based molecular diagnostics company whose Quantitative Counting Templates platform powers prenatal screening and the Northstar oncology franchise; it went public in November 2025 and carries a market value of roughly $4.6 billion. On Wednesday the stock slid 9.59% to $88.15, compared with Tuesday's close of $97.50, putting the shares at their lowest level since early September. The direction was decisively negative from the pre-market session onward. The immediate reason cited by the market is a bearish research report from short-seller Fuzzy Panda Research, which disclosed its own short position and alleged problematic reimbursement practices, undisclosed regulatory scrutiny and weak differentiation in the company's cancer tests.
The report, circulated before Wednesday's open, leans on state public-records requests, interviews with unnamed former employees and conversations with physicians. Its central claim is that Tennessee's Office of Program Integrity opened an inquiry in 2024 after receiving 11 tips and referred the matter to the Tennessee Bureau of Investigation's Medicaid Fraud Control Division — scrutiny the report says was never disclosed in securities filings. Fuzzy Panda also points to Michigan Medicaid data showing carrier screening billed alongside roughly 88% of non-invasive prenatal tests, and argues patient deductible and copay caps of $99 to $349 were applied without income verification.
Two features of the report explain why the market reaction was sharp. First, it attacks the durability of revenue rather than a single quarter, arguing that curbing what it calls excess carrier-screening claims could cut EBITDA by about 80%. Second, it puts a headline number on legal risk, modeling hypothetical False Claims Act penalties above $1.2 billion — more than a quarter of the company's market capitalization. That figure is the firm's own estimate, and a law-enforcement referral does not establish wrongdoing or the filing of charges. BillionToOne has not publicly addressed the allegations.
The report landed on a stock that was already under distribution. BLLN peaked near $150 in early August, slid 38.9% in a single session on August 6, and then rallied back toward $115 by late October before rolling over again. Coming into Wednesday, the shares had dropped 5.1% on November 13 and 8.4% on November 16, breaking below both the 50-day average near $106.90 and the 200-day average near $97.80. That left little technical support beneath Tuesday's close, and momentum indicators had already turned negative before the report existed — a condition that tends to magnify the impact of adversarial research.
Turnover has been running hot relative to history: the two prior sessions each cleared 400,000 shares against a 60-session average of roughly 293,000, and elevated activity has persisted since the November 5 post-earnings session. The move was idiosyncratic. The iShares Biotechnology ETF and the SPDR Biotech ETF were both modestly higher on the day, and peer MYGN gained more than 2%, while NTRA slipped less than 2%. The Nasdaq-100 proxy was fractionally lower. In other words, nothing in the sector tape accounts for a near-10% decline in this name.
The score runs from 0 — no meaningful news and an ordinary move — to 100, meaning transformative news and an extreme, rare price move. This event lands at 58 out of 100. The verified news is substantial in its own right: a short-seller report alleging undisclosed regulatory scrutiny and challenged reimbursement practices against a $4.6 billion company is material, even though the claims remain unproven and the company has not responded. The price move is unusual but not extreme: 9.59% is about 3.6 times the stock's 2.7% average daily swing, and only two of the last 60 sessions produced an equal or larger absolute change. Moderate news plus a moderately rare move combine into a mid-range score.
The immediate focus is whether BillionToOne issues a formal rebuttal, and whether any state or federal agency confirms or disputes the report's characterization of its billing history. The company's next scheduled milestone is the December 15 commercial launch of Northstar Clear, its tissue-free minimal residual disease test, following third-quarter revenue of $123 million, up 47% year over year, and raised full-year guidance of $460 million to $470 million. Fourth-quarter results and 2027 guidance will be the next hard test of the reimbursement narrative. Risks include further short-seller follow-ups, reimbursement disputes with payers, rising days sales outstanding, heavy insider selling under pre-arranged plans, and the stock's history of double-digit single-session swings. Analysts remain broadly constructive, with most ratings at buy and an average target well above the current price, though those targets now face a credibility test.
Tickeron's Trending AI Robots page curates the platform's strongest current performers from a universe of hundreds of AI trading bots spanning thousands of tickers. Because bots differ widely by strategy, timeframe, performance metrics and traded symbols, the page narrows the field to those best suited to prevailing market conditions. It is a practical starting point for traders who want to see how automated strategies are positioned right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BLLN saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator turned negative. In 19 of the 21 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for BLLN turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 9 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BLLN moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BLLN crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for BLLN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for BLLN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLLN advanced for three days, in 48 of 54 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
BLLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. BLLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.016) is normal, around the industry mean (67.298). BLLN has a moderately high P/E Ratio (136.508) as compared to the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (12.195) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalSpecialties